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Abstract: South African women have a high rate of cervical cancer cases, but there are limited
data on human papillomavirus (HPV) genotypes in cervical intraepithelial neoplasia (CIN) in the
Eastern Cape province, South Africa. A total of 193 cervical specimens with confirmed CIN from
women aged 18 years or older, recruited from a referral hospital, were tested for HPV infection.
The cervical specimens, smeared onto FTA cards, were screened for 36 HPV types using an HPV
direct flow kit. HPV prevalence was 93.5% (43/46) in CIN2 and 96.6% (142/147) in CIN3. HIV-
positive women had a significantly higher HPV prevalence than HIV-negative women (98.0% vs.
89.1%, p = 0.012). The prevalence of multiple types was significantly higher in HIV-positive than HIV-
negative women (p = 0.034). The frequently detected genotypes were HPV35 (23.9%), HPV58 (23.9%),
HPV45 (19.6%), and HPV16 (17.3%) in CIN2 cases, while in CIN3, HPV35 (22.5%), HPV16 (21.8%),
HPV33 (15.6%), and HPV58 (14.3%) were the most common identified HPV types, independent of
HIV status. The prevalence of HPV types targeted by the nonavalent HPV vaccine was 60.9% and
68.7% among women with CIN2 and CIN3, respectively, indicating that vaccination would have an
impact both in HIV-negative and HIV-positive South African women, although it will not provide
full protection in preventing HPV infection and cervical cancer lesions.
Keywords: human papillomavirus; human immunodeficiency virus; cervical intraepithelial lesions;
South Africa
1. Introduction
Human immunodeficiency virus (HIV) infection is highly predominant in Africa. Glob-
ally, approximately 25.7 million people live with HIV infection, of which 80% (20.7 million)
reside in Eastern and Southern Africa, as reported in 2019 [1,2]. Of the African countries,
South Africa has the largest population affected by HIV infection, with 7.5 million people
living with HIV and 200,000 new infections reported in 2019 [3]. HIV prevalence is esti-
mated to be 19.0% among women aged 15–49 years [2,3]. Among the nine provinces in
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South Africa, the prevalence of HIV infection for adult women aged 15–49 years ranges
from 12.6% to 27.0%, with high rates observed in Kwazulu-Natal province (27.0%), Free
State province (25.5%), and Eastern Cape province (25.2%) [4].
An interaction between HIV infection and specific cancers has been established. Cervi-
cal cancer is one of the three cancers established as AIDS-defining cancers [5]. South Africa
ranked as the country with the fourth highest number of cervical cancer cases among HIV-
positive women (63.4%) in 2018 [6]. The incidence rate of cervical cancer was estimated
to be 506 per 10,000 person-years among HIV-positive South African women in 2017 [7].
Cervical cancer arises from cervical intraepithelial neoplastic lesions (CIN) stages 1–3 and is
causally associated with genital human papillomavirus (HPV) [8,9]. HIV-positive women
have an increased burden of genital HPV acquisition, high-risk (HR) HPV persistent infec-
tion, multiple infections of HR-HPV, and precancerous lesions compared to HIV-negative
women [10,11]. Studies suggest that this results from immune suppression and low CD4
cell count [10,12].
Persistent infection with HPV16, HPV18, and other HR-HPV genotypes is the most
significant risk factor for developing cervical lesions and cervical cancer [13]. HPV16/18
are essential HR-HPV types that significantly contribute to cervical cancer disease progres-
sion [14]. There are different strategies implemented to prevent preinvasive lesions and
cervical cancer, mainly through HPV vaccination and cervical cancer screening. The type-
specific HPV vaccines, namely, bivalent (HPV16/18), quadrivalent (HPV16/18/6/11),
and nonavalent (HPV16/18/6/11/31/33/45/52/58), have been introduced in more than
forty countries, both developing and developed [15–17]. These vaccines are offered to ado-
lescent and young women aged 9–26 years [15,16]. In South Africa, a national school-based
vaccination campaign for the bivalent HPV vaccine was implemented to target public
school girls aged nine years in grade 4. An uptake of the bivalent HPV vaccine ranging
from 87% to 92% was positively attained among South African girls [18,19]. However,
cervical cancer screening among older women is still necessary, as they are beyond the
targeted age for receiving the HPV vaccine and more likely to have been infected with HPV.
Molecular HPV DNA testing has been implemented as the alternative to non-molecular
testing for cervical cancer, particularly cytology testing [20]. HPV testing is utilised in vari-
ous strategies for screening, such as triage, co-testing, or HPV testing alone [21], and has
high sensitivity but low specificity for the detection of CIN2/3 [22,23].
There is limited information on the epidemiology of HPV types in women with
preinvasive cervical lesions from the Eastern Cape province. It is essential to investigate
the prevalence of HPV genotypes and their distribution among women with different
immune statuses and confirmed CIN histology results in this region. Therefore, these data
will help achieve better understanding of the HR-HPV types involved in cervical lesions
and cervical cancer cases. Furthermore, this information will contribute to discussions
about implementing strategies for cervical screening and monitoring HPV types that are
not present in the current vaccines to reduce cervical cancer disease in this population.
Our study aims at investigating the distribution of HPV genotypes among HIV-positive and
HIV-negative women with cervical intraepithelial lesions from Eastern Cape, South Africa.
2. Material and Methods
2.1. Study Population
The study obtained ethical approval from the Human Ethics Committees of the Univer-
sity of Cape Town (UCT, HREC reference 615/2017), Walter Sisulu University (016/2017),
and Eastern Cape Department of Health (EC reference 2017RPO_484). The recruitment
procedure for this study was reported previously [24]. Briefly, between September 2017
and March 2019, cervical specimens were collected among women referred to the Nelson
Mandela Academic Hospital Gynaecology Outpatient Clinic located in the OR Tambo
municipality area in the Eastern Cape province, South Africa. A total of 193 women were
recruited, aged ≥18 years, with atypical squamous cells of undetermined significance
(ASCUS), atypical squamous cells cannot exclude high-grade lesions (ASC-H), atypical
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glandular cells, not otherwise specified (AGC-NOS), low-grade squamous intraepithelial
lesions (LSIL), and high-grade squamous intraepithelial lesions (HSIL). The cervical speci-
mens were collected by a study nurse using a Viba-brush (Rovers Medical Devices B.V.,
5347 KV Oss, Netherlands, smeared onto FTA cards (GE Healthcare, Amersham place
little Chalfont, Buckinghamshire HP7 9NA, UK), and shipped at room temperature to
UCT. The cervical biopsy was collected for histopathology and was performed by the
National Health Laboratory Service. Based on the histopathology results, 46 women with
CIN2 and 147 with CIN3 were included in this study. All eligible women provided signed
consent forms.
2.2. Detection of HPV Genotypes
DNA elution of cervical specimens from FTA cards was done following the procedure
previously described [24,25]. Four microlitres of extracted DNA was used for HPV test-
ing. Detection of HPV genotypes was performed using an HPV direct flow chip kit on a
Hybrispot machine (Master Diagnostica, Granada, Spain) following the manufacturer’s
procedure. The HPV direct flow chip protocol is a PCR-based method based on the amplifi-
cation of a viral DNA fragment, followed by hybridisation onto a membrane chip using
the amplified PCR products. The chip membrane contains DNA control, hybridisation
control, PCR control, and probes for genotype-specific HPV detection. The assay detects
36 HPV genotypes (low-risk HPV: 6, 11, 40, 42, 43, 44, 54, 55, 61, 62, 67, 69, 70, 71, 72, 81,
84, and 89 (C6108) and high-risk HPV:16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66,
68, 73 and 82). Each chip membrane’s results were captured by a camera and analysed
automatically using HybriSoft software (Master Diagnostica, Granada, Spain) [26].
2.3. Data Analysis
All data and statistical analyses were done using GraphPad Prism version 6 (GraphPad
Software, La Jolla, CA, USA). The chi-squared test was used to determine a statistical
difference between HPV infection and variables. A variable was considered significant if
the p-value was < 0.05.
3. Results
3.1. Description of Study Participants
The median age of women was 40 (IQR: 33–48) years. A high number of women were
HIV-positive (76.2%) and never smoked (93.3%), and half of the women had their first
sexual experience at the age of 16–18 years (53.9%) (Table 1). Women were more likely
to have ≥3-lifetime sexual partners (62.7%), with a high proportion having high-grade
squamous lesions on cytology testing (75.1%) (Table 1).
3.2. HPV Prevalence According to HIV Status
Of the 193 women screened, 93.5% (43/46) with CIN2 and 96.6% with CIN3 had an
HPV infection. HIV-positive women had a significantly higher prevalence of any HPV
infection compared to HIV-negative women (98.0% vs. 89.1%, p = 0.012) (Table 2). HIV-
negative women were almost 2-times more likely to have only a single HPV infection
compared to HIV-positive women, although there was no statistical significance (OR: 1.45;
CI: 0.735–2.867, p = 0.282, Table 2). However, HIV-positive women had a significantly
higher HPV prevalence compared to HIV-negative women (65.3% vs. 47.8%, p = 0.034,
Table 2). For multiple infections, the median of HPV types was 2 (range: 2–11). When
stratified by HIV status, there was no significant distinction between HIV-negative and
HPV-positive women (Figure 1).
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Table 1. Demographic and behavioural characteristics of study participants.
Variables % (n/N)





18–29 years 11.4% (22/193)
30–39 years 35.2% (68/193)
40–49 years 35.2% (68/193)
≥50 years 18.1% (35/193)
Highest level of education attained
Never/primary 29.5% (57/193)






Former/current smoker 6.2% (12/193)
Age at first sexual experience
<16 years 21.2% (41/193)
16–18 years 53.9% (104/193)









ASCUS: atypical squamous cells of undetermined significance; ASC-H: atypical squamous cells cannot exclude
high-grade lesions; AGC-NOS: atypical glandular cells, not otherwise specified; LSIL: low-grade squamous
intraepithelial lesions; HSIL: high-grade squamous intraepithelial lesions.
Table 2. Prevalence of HPV infection according to HIV status.
Variables HIV-Negative, N = 46 HIV-Positive, N = 147 OR (95%CI) p-Value
Any type 89.1% (41/46) 98.0% (144/147) 0.17 (0.039–0.745) 0.012
Single infection 41.3% (19/46) 32.7% (48/147) 1.45 (0.735–2.867) 0.282
Multiple infection 47.8% (22/46) 65.3% (96/147) 0.49 (0.249–0.953) 0.034
HR-HPV types 82.6% (38/46) 87.1% (128/147) 0.71 (0.286–1.738) 0.446
Probable HR-HPV
types 17.4% (8/46) 30.6% (45/147) 0.60 (0.260–1.394) 0.233
LR-HPV 39.1% (18/46) 44.2% (65/147) 0.81 (0.413–1.594) 0.543
HR-HPV: high-risk human papillomavirus; LR-HPV: low-risk human papillomavirus; OR: odds ratio; CI: confidence intervals.
3.3. HPV Distribution According to Cervical Intraepithelial Lesions and HIV Status
Women with CIN2 were more likely to be infected with two HPV types (Figure 2A).
The most frequently detected HPV types were HPV35 (23.9%), HPV58 (23.9%), HPV45
(19.6%), and HPV16 (17.3%) (Table 3). Among single HPV infections, HPV35 and HPV16
were more frequent in HIV-negative women, while HPV16 and HPV52 were detected
in HIV-positive women (Figure 3). For multiple HPV infections, HPV35, HPV58, and
HPV45 were common in HIV-positive women, whereas HPV35, HPV58, and HPV16 were
frequently detected among HIV-negative women (Figure 3).
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Table 3. Distribution of HPV genotypes among women with CIN2 and CIN3 from a referral hospital.
HPV Types All Women % (n/N) CIN2 % (n/N) CIN3 % (n/N)
16 20.7% (40/193) 17.4% (8/46) 21.8% (32/147)
18 8.8% (17/193) 10.9% (5/46) 8.8% (12/147)
31 11.4% (22/193) 8.7% (4/46) 12.2% (18/147)
33 13.0% (25/193) 4.4% (2/46) 15.6% (23/147)
35 22.8% (44/193) 23.9% (11/46) 22.5% (33/147)
39 6.2% (12/193) 2.2% (1/46) 7.5% (11/147)
45 15.0% (29/193) 19.6% (9/46) 13.6% (20/147)
51 6.7% (13/193) 6.5% (3/46) 6.8% (10/147)
52 13.5% (26/193) 15.2% (7/46) 12.9% (19/147)
56 8.3% (16/193) 4.4% (2/46) 9.5% (14/147)
58 16.6% (32/193) 23.9% (11/46) 14.3% (21/147)
59 2.6% (5/193) 4.4% (2/46) 2.0% (3/147)
26 4.1% (8/193) 4.4% (2/46) 4.1% (6/147)
53 0.5% (1/193) 0.0% (0/46) 0.7% (1/147)
66 8.3% (16/193) 8.7% (4/46) 8.2% (12/147)
68 4.1% (8/193) 4.4% (2/46) 4.1% (6/147)
73 2.6% (5/193) 4.4% (2/46) 2.0% (3/147)
82 10.4% (20/193) 6.5% (3/46) 11.6% (17/147)
6 6.2% (12/193) 6.5% (3/46) 6.1% (9/147)
11 4.7% (9/193) 0.0% (0/46) 6.1% (9/147)
40 3.6% (7/193) 2.2% (1/46) 4.1% (6/147)
42 7.3% (14/193) 8.7% (4/46) 6.8% (10/147)
43 2.1% (4/193) 0.0% (0/46) 2.7% (4/147)
44/55 10.9% (21/193) 17.4% (8/46) 8.8% (13/147)
54 3.6% (7/193) 6.5% (3/46) 2.7% (4/147)
61 0.5% (1/193) 0.0% (0/46) 1.4% (1/147)
62/81 15.0% (29/193) 19.6% (9/46) 13.6% (20/147)
70 4.1% (8/193) 6.5% (3/46) 3.4% (5/147)
71 4.7% (9/193) 2.2% (1/46) 5.4% (8/147)
72 3.6% (7/193) 6.5% (3/46) 2.7% (4/147)
HPV: human papillomavirus; CIN: cervical intraepithelial neoplasia. Bold indicates the most dominant HPV types.




Figure 2. Distribution of single and mu tiple HPV types ac ording to age i  women with CIN2 (A) and CIN3 (B). 
 
Figure 3. Distribution of HPV types among women with CIN2 in single and multiple infections according to HIV status. 
Figure 3. Distribution of HPV types among women with CIN2 in single and multiple infections according to HIV status.
Women with CIN3 were more likely to be infected with two HPV types (Figure 2B).
Their commonly identified HPV types were HPV35 (22.5%), HPV16 (21.8%), HPV33 (15.6%),
and HPV58 (14.3%) (Table 3). In single infections, HPV16, HPV35, and HPV33 were
mostly observed in HIV-negative and HIV-positive women (Figure 4). However, the most
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detected HPV types in multiple infections were HPV16, HPV35, and HPV66 in HIV-
negative, whereas HPV16, HPV35, and HPV45 were observed among HIV-positive women
(Figure 4).
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4. Discussion
This study investigated the prevalence and distribution of HPV types among HIV-
positive and HIV-negative women with high-grade precancerous cervical lesions. A high
number of women in this study were HIV-positive (76.2%). A significantly high overall
prevalence of any HPV infection (98% vs. 89%) and multiple infections (65% vs. 49%)
was observed among HIV-positive compared to HIV-negative women with cervical in-
traepithelial lesions. This higher prevalence of multiple types of HPV infection among
women with HIV infection agrees with other cohorts of women with high-grade lesions
from Botswana and South Africa [27–29]. However, in a South African study by Van
Aardt and colleagues (2016), the rate of multiple HPV infections among HIV-positive and
HIV-negative women (81.3% vs. 64.4%) with confirmed CIN2/3 was higher compared
to our study [29]. This difference could be attributed to the various assays used for HPV
testing and the different study populations.
A high prevalence of HPV in women with CIN2 (93.5%) and CIN3 (96.6%) was
observed in this study, which is expected as these women had abnormal cytology from the
referral clinic. Similarly, a high HPV prevalence was reported in a global meta-analysis
study, whereby HPV prevalence ranged from 86% to 93% in women with high-grade lesions
(CIN2/3) [30]. In the present cohort, HPV35 was the most predominant HPV type among
participants with CIN2 lesions, while in those with CIN3 lesions, HPV16 and HPV35
were the most frequently detected HPV genotypes, either as a single HPV infection or
multiple infections, regardless of HIV status. This observation was similar to other studies
from South Africa and Kenya, where HPV16 and 35 were the most common genotypes in
HIV-positive or HIV-negative women with high-grade squamous intraepithelial lesions or
CIN2/3 [28,31]. However, a study among sex workers from Kenya showed that HPV52
was the most prevalent HPV type and more likely to be present as a single infection
in women with severe lesions (HSIL/SCC) [32]. Furthermore, a recent cross-sectional
study by Dovey (2018) among women from four developed countries (Iceland, Norway,
Sweden, and Denmark) reported a different distribution of HPV types, with HPV16, 31,
and 52 present in CIN2 cases and HPV 16, 31, and 33 detected in CIN3 cases [33]. The high
occurrence of HPV35 in this population and other African studies of women with invasive
cervical cancer suggests an interaction between HPV35 and cervical carcinogenesis [34–36].
Therefore, preventative strategies are needed, as the HPV35 genotype is present in up to
10% of sub-Saharan African women with invasive cervical cancer [36–39] and not present
in the current HPV vaccines.
Previously, cervical histological lesions were associated with one HPV type [40].
However, in the present cohort, most high-risk HPV types and probable high-risk HPV
types occurred as multiple HPV infections both in CIN2 and CIN3 cases. Multiple infections
are reported as the risk factor of persistent infection and associated with high-grade CIN2/3
cases compared to a single infection [41]. Women with multiple HPV types have been
found to have larger cervical lesions and are associated with poor responses to cervical
cancer treatment [42,43]. Kaliff et al. (2018) reported a significantly high recurrence rate of
cervical cancer among women with multiple HPV infections compared to a single HPV
infection (44.0% vs. 24.0%) and a low cancer survival rate [42]. Furthermore, the high
prevalence of multiple HPV infections in the present study could be because HPV testing
was performed on cervical cells instead of biopsy specimens. Therefore, it is not possible to
determine which HPV types caused the lesion and which infected other parts of the cervix.
HPV testing on biopsies eliminates the detection of multiple HPV infections, and multiple
HPV infections are observed to be significantly lower in biopsies compared to exfoliated
cells from invasive cervical cancers [39,44].
Interestingly, in our study, HPV16 was not the predominant HPV type, as it ranked
fourth in CIN2 and second in CIN3 cases in the present cohort. A low prevalence of HPV16
has been observed in other sub-Saharan studies, while a high prevalence was observed
in European studies [45–47]. These findings could be explained by the population being
sampled from different geographical areas, host genetic difference/host immunogenic
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factors, and the biological interplay between HPV types [48]. It is important to do a study
based on cervical cancer biopsies to determine which HPV types are causally involved
in cervical cancer in this community. The distribution of HPV types in this study are
concerning, as there are many types that are not in the available vaccines.
Persistent HR-HPV infection is regarded as a significant factor in the development of
cervical cancer lesions. However, in the current study, 4.2% (8/193) of women with CIN2/3
were negative for any HPV type, and seven of these samples were also negative when
typed with hpVIR real-time PCR [24]. One specimen was positive on hpVIR real-time PCR
for HR-HPV infection (HPV59) but had a low HPV copy number (11.3 copies) and viral
titre (0.052). The observed negative results of HPV infection in women with high-grade
lesions may suggest that it could result from sample storage, inadequate sampling, or low
viral load. Alternatively, there may be novel HPV types causing the cancers that are not
detected by the test used.
The currently available HPV vaccines are estimated to prevent 70–90% of cervical
cancer cases [49]. The nonavalent HPV vaccine has been highly effective in preventing HPV
infection and cancer diseases, with efficacies ranging between 90% and 100% [15,50–52].
A study reported by Garland and colleagues (2018) in Asian women showed that nonava-
lent significantly decreased the risk of persistent infection, abnormal cytology, and diseases
caused by specific HPV types targeted by this vaccine [50]. In the present study, HPV
vaccines could protect 20–69.0% of CIN2/3 cases in women with or without HIV infection.
Therefore, the high prevalence of HPV types targeted by the nonavalent HPV vaccine
suggests that introducing this HPV vaccine would be beneficial, as most precancerous
lesions could have been prevented. However, the predominant HPV genotype (HPV35) in
this population, which accounts for 24% in CIN2 and 23.0% in CIN3, is not covered by the
nonavalent HPV vaccine.
Vaccines have been found to provide cross-protection against specific vaccine HPV
types as well as some types that are not present in the vaccine. Numerous trial studies
have reported that the bivalent vaccine offers a wider extent of cross-protection against
nonvalent specific types (31/33/45/52/58), with less extensive cross-protection by Gardasil-
9 [53–55]. Studies have reported that bivalent showed substantial cross-protection against
HPV31/33/45 but less so against HPV35 and HPV58 after seven to eight years postvaccina-
tion [53,56,57]. A study by Brown and colleagues (2009) among younger women aged 16–
25 years vaccinated with the quadrivalent HPV vaccine showed a reduction of high-grade
lesions (32.5%) related to ten non-vaccine HPV types (31/33/35/39/45/52/52/56/58/59)
known to cause cervical cancer after 3.6 years of follow-up [58]. Therefore, this suggests
that cross-protection might have played a role and that the benefits of vaccination could
include protection from clinically relevant HPV types not included in the vaccines [58].
The cross-protection is related to the phylogenetic distance between the HPV types, as they
are all closely related to vaccine types and found in the alpha-9 group [56]. However,
since cross-protection against HPV35 is observed to be less efficient compared to other
HPV types, the addition of HPV35 to the next-generation HPV vaccine would improve the
effectiveness of the HPV vaccine, especially in Africa.
5. Conclusions
We observed a significantly higher prevalence of HPV and multiple HPV infections
in HIV-positive compared to HIV-negative women with cervical intraepithelial lesions.
The distribution of HPV genotypes was similar between CIN2 and CIN3 cases indepen-
dently of HIV status. The HPV nonavalent vaccine would have an impact on South African
women, although it will not provide full protection in preventing HPV infection and
cervical cancer lesions. Therefore, the high prevalence of the non-vaccine type (HPV35)
underscores the need to incorporate this HPV type into the next HPV vaccines. This
study also highlights the importance of introducing cervical cancer screening strategies to
monitor non-vaccine HPV types.
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